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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
complimentary and alternative medicines are safe and effective in improving symptoms of adult
patients over the age of 18 with active Crohn disease.
Study design: A review of three published, randomized controlled trials (RCTs), one published
in 2010, and the second and third in 2014. All English language.
Data source: All 3 RCT’s were found using PubMed.
Outcomes measured: All three studies measured improvement of Crohn disease symptoms
through the Crohn Disease Activity Index (CDAI), Hamilton’s Depression Scale (HAMD), the
Inflammatory Bowel Disease Questionnaire (IBDQ) and the Partial Harvey Bradshaw Index
(pHBI).
Results: Patient reported improved health-related quality of life and gastrointestinal function
Conclusions: The studies demonstrate some evidence that Complimentary and Alternative
Medicines may improve acute symptoms of Crohn disease and an increased quality of life.
However, it is inconclusive whether these therapies actually provide long-term results in healing
patients with chronic disease.
Key words: “Crohn Disease” & “Complimentary Therapies”
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Introduction
Crohn Disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of
the gastrointestinal (GI) tract from mouth to anus.1 IBD is comprised of CD and ulcerative colitis
(UC). CD is a chronic, relapsing and remitting disease characterized characterized by chronic
diarrhea, abdominal pain and weight loss. Complementary and alternative medicine (CAM) is a
term used to describe health and wellness therapies that have typically not been part of
conventional Western medicine. “Complementary” suggest therapies that are used in conjunction
with conventional medicine. “Alternative” suggests therapies used in substitution to conventional
medicine.2 This study evaluates the efficacy of CAMs in improving the symptoms associated
with active CD.
Collectively, it is estimated that 1 in 200 Americans live with IBD.3 The incidence is
evenly divided between CD and UC in the US. Studies have extrapolated that the direct medical
costs based on insurance claims for all patients treated for IBD estimated up to 28 billion dollars
in 2014.6 These costs include hospitalizations, prescription drugs, over the counter medications,
hospital and physician services. Between 2011-2013, health plans estimated to pay out costs of
$18,637 per patient with CD.6 Considering that the most common presenting symptom of CD is
abdominal pain, this disease remains to be a diagnostic challenge for many clinicians across the
medical landscape.4
With the increasing popularity and influence of eastern medicine on western medicine,
patients have greater access to complimentary and alternative therapies. The trend of “natural”
remedies or holistic medicine has a place in today’s advancing medicine for both the patient and
the consumer. Some of the most popular internet searches for alternative therapies include
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acupuncture, Ayurveda medicine, chiropractic care and biofeedback. The utilization of CAMs in
clinical trials offer insight to their safety and efficacy in treating a myriad of conditions.
There are many natural remedies to treating abdominal pain. However, CAM
interventions used in studies to treat CD aim at targeting more symptoms of the disease.
Examples include the herb Artemisia absinthium, commonly known as wormwood; it is best
known as the main ingredient in the alcoholic drink, absinthe. Another is acupuncture, a therapy
that inserts small needles into specific zones of the body in order to stimulate an immune
response. Moxibustion, or dried mugwort, is traditional Chinese herb used to augment medical
therapies to increase healing.5 Lastly, diet is not well understood in CD. Some foods have been
linked to inflammation, which has a direct affect with symptoms of CD.6
The exact cause of CD is unknown, however it is understood to be involve interacting
factors such as genetics, immune system and our personal environments.6 The emotional impact
from sudden flair ups to embarrassing GI symptoms increases stress levels, which can weaken
immune systems. Like many disease states of dysfunctional immune systems, there is no cure; or
one specific treatment that is effective in all patients. Treatment approach is highly complex.
Biologic agents such as TNF inhibitors are one of the current emerging treatments for CD. They
have been shown to induce and maintain clinical remission in patients with moderate to severe
CD.6 The many side effects and the administration of these drugs make them less appealing to
some patients.
Objective
The objective of this selective EBM review is to determine whether or not CAMs are safe
and effective in improving symptoms of adult patients over the age of 18 with active CD.
Methods
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The criteria used as a basis to this study included participant population, interventions
used, comparison analysis between control groups and measurable outcomes. This review
focused on a population of participants over the age of 18 with active CD. The interventions used
in all three RCT’s were different types of complimentary and alternative medicines. These
interventions were analyzed in comparison to participants over the age of 18 with active CD
utilizing a placebo specific to each respective study. The outcomes that are measured include
improvement of gastrointestinal-related and general symptoms of CD, improvement in healing,
and an increased quality of life.
The intervention used in the study Krebs et al., included powdered wormwood capsules
versus the control placebo.7 Bao et al., compared the study group of participants receiving a
combination of acupuncture augmented with moxibustion, against a control group of participants
receiving placebo “superficial” acupuncture and moxibustion.8 Interventions addressed in the
Brotherton et al. study focused on patients consuming a high fiber, low refined carbohydrate
diet, with specific daily consumption of whole wheat bran cereal. This was compared against a
control group consuming a modified elimination diet.9
Article search and selection for this selective EBM review was conducted through
PubMed. The key words used in the search were “Crohn Disease” and “Complimentary
Therapies”. The studies chosen were all published in peer-review journals between 2010 and
2014. All 3 studies were written in English and selected based on the preceding criteria, being
patient-oriented evidence, as well as the clinical relevance to my question. Statistical data
reported to determine clinical importance included p-value, relative risk reduction (RRR),
absolute risk reduction (ARR), and number needed to treat (NNT)
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Table 1 Demographics & Characteristics of included studies
Study
Krebs
et al.,
2010

Type
RCT

# Pts
20

Age
18-80
years

Inclusion Criteria
Between the age of
18-80
Prior CDAI score of
at least 200 for 3 mo

Bao et
al.,
2014

RCT

92

18-80
years

Broth
erton
et al.,
2014

RCT

7

18-64
years

Diagnosis of mild or
moderate CD;
Negative history of
salicylic acid and/or
prednisone (at a
dose ≤ 15 mg) for at
least 1 month, and
immunosuppressant
or used anti-TNF-α
biological agents for
3 months prior to
enrollment.
Diagnosed with CD
via colonoscopy and
biopsy.
Aged 18 to 64 years
pHBI score ≥3
At least 4 weeks of
stable
pharmacologic
therapy.

Exclusion Criteria
Participants
receiving TNF-alpha
inhibitors

W/D
0

Interventions
Powdered
wormwood
(Artemisia
absinthium)
750mg x3 qd

Pregnant or lactating,
heart, brain, liver,
kidney, or
hematopoietic
disease, mental
illness, other severe
diseases.

15

Acupuncture
and
moxibustion

Use of Biologics,
diverticulitis, short
bowel syndrome,
clinically significant,
penetrating or
stricturing CD,
Special dietary
restrictions, any
disorder that might
interfere with the
ability to follow
detailed dietary
instructions over
time, pregnancy;
cancer, uncontrolled
kidney or CVD,
pHBI score >9.
decompensated liver
disease.

0

High fiber and
low refined
carbohydrate
diet; including
consumption
of whole wheat
bran cereal.

Outcomes Measured
The main outcome in the Krebs et al. study was the improvement of CD symptoms
measured through the Crohn Disease Activity Index (CDAI).7 Participants were required to have
a minimum CDAI score of at least 200 at baseline.7 This study also collected secondary
outcomes of improved mood, measured by the Hamilton Depression Scale (HAMD) and serum
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inflammatory markers.7 Outcomes measured in the Bao et al. study were also aimed at
improvement of symptoms through CDAI.8 The study measured quality of life scores as
secondary outcome through the Inflammatory Bowel Disease Questionnaire (IBDQ).8 The
Brotherton et al. study addresses the effects of a high fiber diet on both the quality of life and
gastrointestinal function of participants with CD.9 These effects were measured through IBDQ
and the partial Harvey Bradshaw Index (pHBI).9 Systemic inflammation was measured in the
blood as secondary outcome for this study.
Results
A total of 20 participants were enrolled in the Krebs et al. study with zero withdrawal
during the 6-week trial.7 Ten participants were randomly selected and divided into the group
receiving wormwood, and the remaining ten were instructed not to take any additional
medications, as comparison.7 Participants who were being actively treated for CD with either 5aminosalicylates, azathioprine or steroids, were kept on a stable dosage prior to the start of the
trial.7 This study excluded patients who were taking TNF inhibitors to avoid comparison from a
pharmacologic prospective.7 There were no significant differences between each participant in
regards to age, duration of disease, extra-intestinal manifestations, and current medications.7
Participants in the wormwood group were instructed to take one 750mg capsule
containing powdered wormwood three times daily for 6 weeks.7 A significant improvement was
defined by the author as a decrease in CDAI score of 70 points or decrease in HAMD scores of
50% from baseline.7 At the end of 6 weeks, CDAI scores for the wormwood group decreased by
an average of 100 points, with remission of symptoms in 8 participants.7 Based on the outcomes
measured, this was deemed a significant improvement as compared to a decrease of only 22
points in the control group.7 Control also reports remission of 2 patients at the end of the 6 week
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trial.
Of the secondary outcomes measured, there were reported improvements in mood
symptoms. Participants in the wormwood group showed a decrease in their HAMD scores by an
average of 9.9 points, as compared to the placebo group with a decrease of 3.5 points.7 To
scientifically measure the reduction in pro-inflammatory cytokines, TNF-a levels were drawn at
baseline, 3 and 6 weeks.7 By the sixth week, serum levels reduced an average of 17.5pg/ml for
wormwood, whereas only 2.6pg/ml for control.7 Based on all reported data in Krebs et al. study,
the relative risk reduction (RRR) was 3%, the absolute risk reduction (ARR)was 60% and the
numbers needed to treat (NNT) was 2.7 Table 2 and 2a summarizes the primary outcome and
efficacy of treatment.
Table 2: Krebs et al. primary outcome: improve symptoms of CD per CDAI scores.
Table 2a: efficacy of wormwood treatment on CD symptoms
Wormwood Group (n=10)

Control Group (n=10)

Score

Baseline

6 weeks

Mean

Baseline

6 weeks

Mean

CDAI

275 ± 15

175 ± 12

100

282 ± 11

260 ± 14

22

CER

EER

RRR

ARR

NNT

20%

80%

3%

60%

2

There were 92 participants between the ages of 18-80 enrolled in the 12 week Bao et al.
study with 7 withdrawals before completion.8 Treatment versus placebo were divided between
43 and 42 participants, respectively.8 Of those, 40 of the treatment group and 37 of the control
group completed a follow-up study at week 24.8 There were no significant differences in
participants in terms of baseline data.8 There were two adverse events reported in the study. One
treatment participant reported pain, and one control participant reported burning.8 At the
conclusion, there was a 13% loss to follow up of the subjects who entered the trial.8
Based on the results, CDAI scores from both groups reduced by the end of 12 weeks and
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scores remained low for the treatment group by the 24 week follow up.8 Clinical significance is
determined by a decrease in 70 points on the CDAI scale. There was 83.7% improvement of
symptoms for the treatment group and 40.5% for the control.8 Based on this reported data the
RRR was 1.1%, the ARR was 41.3% and NNT was 2.8 While both groups reported increase in
quality of life through their IBDQ scores, the treatment group score was statistically greater with
a difference of p-value, P = 0.017.8 The study found statistical evidence (p <0.001) that treatment
with acupuncture and moxibustion did improve symptoms of CD per CDAI scores. Table 3
summarizes these results.
Table 3: Bao et al. mean values of CDAI and IBDQ scores.
Table 3a: Efficacy of acupuncture and moxibustion treatment on CD symptoms
CDAI

Treatment Group (n=43)
Baseline
12 weeks
24 weeks
210.84 ± 48.03 -115.35 ± 55.05 -128.93 ± 64.46

CER

EER

RRR

40.5%

83.7%

1.1%

Control Group (n=42)
Baseline
12 weeks
24 weeks
201.04 ±
-35.68 ±
-14.32 ±
57.13
46.91
52.09
ARR
NNT
43.2%

2

Seven participants between ages 18-64 years were enrolled into the Brotherton et al.
study.9 The participants had active CD symptoms and treated as outpatient clinic setting.9 Four
participants were instructed on the intervention diet, which consisted of high fiber, including 0.5
cup of wheat bran cereal, and low refined carbohydrate diet.9 The remaining three participants in
the control group were instructed on a modified elimination diet based on “problematic foods” as
per the Crohn and Colitis Foundation of America. Examples included whole grains, dairy
products, and spicy foods.10 Due to lack of variability in participant pool, only females were
enrolled into the control group. There were no adverse events reported in the study.9
The author reports quality of life of the patients through IBDQ scores, with the range
from 32-224.9 IBDQ measures bowel symptoms, systemic symptoms, emotional function, and
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social function. 9 Clinical significance is determined by a score of ≥32-points.9 Clinical remission
has been set at ≥170 points.9 With a baseline mean of 158.3, the treatment group improved their
scores by 44.25 points. The control group had a baseline of 157.7 and increased by 19 points.9
The increase in treatment scores were statistically significant over control (p = 0.028). All
patients enrolled achieved clinical remission based on the IBDQ scale.9 Based on this reported
data the RRR was 0, the ARR was 100%, and NNT was 10. 9
The pHBI scores measured general well-being, abdominal pain, and number of liquid
stools per day.9 This particular study required baseline scores to range between 3-9.9 Improved
GI function was statistically significant (p = 0.008) with all participants of the treatment group
reporting scores of zero, and control group reported scores of three at the end of the 4 week trial.9
Systemic inflammation was measured in the blood as secondary outcome for this study. This
data was dismissed due to lab mishandling. After the 4 weeks, there were no significant
differences reported in CRP (p-value = 0.125) and ESR (p-value = 0.788) values. 9
Table 4: Brotherton et al.. primary outcomes: increased quality of life through IBDQ and
improved GI symptoms through pHBI.
Table 4a: Efficacy of wheat bran diet on CD symptoms
Wheat Bran Group (n=4)

Control Group (n=3)

Baseline

4 wks

Baseline

4 wks

p-value

IBDQ

158.3 ± 20.1

+44.25

157.7 ± 32.0

+19

0.028

pHBI

5.3 ± 1.3

0

4.7 ± 1.5

3

0.008

Discussion
The primary aim of the Krebs et al. study demonstrates not only improvement of
symptoms symptoms of CD, but also clinical remission of 80% of participants who received
treatment. This study suggests that a natural product could provide patients with an alternative
therapy to injectable biologics agents and specifically excluded patients already administering
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them. A potential limitation to using a natural supplement to augment or treat any disease would
be the safety in regulation and validity in its manufacturing. Most dietary products regulated by
the FDA are done so differently than most food and drug products.11 The correlation between
wormwood and the observed improvement in mood seen in HAMD scores is unclear as there is
little evidence that wormwood may have some anti-depressant effect.7
Overall, the use of intervention in the Bao et al. study, provided some observable benefits
for patients suffering from gastrointestinal symptoms secondary to CD. It is said that
acupuncture has been utilized in Chinese internal medicine as a treatment since 100 B.C.12 This
ancient therapy has reputation for alleviating many sub-clinical ailments and boasts little side
effects or adverse reactions.12 As an alternative therapy in combination with partitioned
moxibustion, this appears to be an effective treatment for this particular patient population.
The limitations of this study were observed in the outcomes measured. Unlike the CDAI
scores, the IBDQ and other laboratory values were only recorded post-treatment.8 The primary
efficacy indicator, CDAI, was documented at the 12 and 24 week follow up to ascertain progress
and stability.8 This study also did not address any mood or affective symptoms that are
commonly associated with CD and IBD.
As a whole, the Brotherton et al. study demonstrated ease of implementing an affordable
and tolerable whole wheat food into daily diet, which is beneficial to a population with
advancing need for alternatives in health care. As a complex carbohydrate, wheat bran is
fermentable, which allows it to provide the gut with a rich source of microbiota that would
enhance the natural flora.9 It is also rich in fiber, which slows gastric transit time and increases
the water-binding capacity of luminal contents, ultimately reducing the frequency of diarrhea and
constipation associated symptoms of CD.
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This study was limited by it’s small sample size and potentially by the duration of the
study. There were numerous exclusion criteria, as well as an exclusively female control group. In
the results section, the author comments on the unreliability pertaining to the secondary aim of
this study. regarding the measurements in inflammatory markers. CRP and ESR are both nonspecific lab markers and provide little insight regarding specifics of gastrointestinal
inflammation.9
Conclusion
The three studies reviewed in order to support the question, “Are CAMs safe and
effective in improving symptoms of adult patients over the age of 18 with active Crohn disease?”
demonstrate some evidence that CAMs may improve acute symptoms of Crohn disease and an
increased quality of life. However, it is inconclusive whether these therapies actually provide
long-term results in healing patients with CD. This review is ultimately limited by the use of
different types of CAMs in each of the articles. With no identifiable harms in the above studies,
the discussed interventions could be an alternative option to augment traditional medical
treatment for patients suffering from this chronic and incurable disease. It would benefit future
studies like these to observe participants over a longer period of time, as well as scheduled
follow up visits for those who achieve early remission.
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